Effects of Everolimus Monotherapy on Hematological Parameters and Iron Homeostasis in De Novo Liver Transplant Recipients: Preliminary Results

Transplantation Proceedings

Volumn 40, Issue 6, 2008, Pages 1947-1949

  Masetti, M ^a   Rompianesi, G ^a   Montalti, R ^a   Romano, A ^a   Spaggiari, M ^a   Ballarin, R ^a   Guerrini, G P ^a   Gerunda, G E ^a  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BASILIXIMAB; CYCLOSPORIN A; ERYTHROPOIETIN; EVEROLIMUS; FERRITIN; HEMOGLOBIN; IRON; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; STEROID; TRANSFERRIN;

ANEMIA; ARTICLE; BONE MARROW SUPPRESSION; CLINICAL ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG DOSE REDUCTION; DRUG EFFECT; FEMALE; FERRITIN BLOOD LEVEL; FOLLOW UP; GRAFT RECIPIENT; HEMATOCRIT; HEMATOLOGICAL PARAMETERS; HEMOGLOBIN BLOOD LEVEL; HOMEOSTASIS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; IRON BLOOD LEVEL; IRON DEFICIENCY ANEMIA; IRON HOMEOSTASIS; LEUKOCYTE; LEUKOPENIA; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; MALE; MEAN CORPUSCULAR HEMOGLOBIN; MEAN CORPUSCULAR VOLUME; MICROCYTIC ANEMIA; MONOTHERAPY; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTE; TRANSFERRIN BLOOD LEVEL; TREATMENT DURATION;

ANEMIA; BLOOD VOLUME; CYCLOSPORINE; HEMOGLOBINS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; IRON; LEUKOCYTE COUNT; LIVER TRANSPLANTATION; PLATELET COUNT; PROSPECTIVE STUDIES; SIROLIMUS;

EID: 48049120445     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transproceed.2008.05.068     Document Type: Article

References (8)

1. Maheshwari A., Mishra R., and Thuluvath P.J. Post-liver-transplant anemia: etiology and management. Liver Transpl 10 (2004) 165
2. Sánchez Fructuoso A., Calvo N., and Moreno M.A. Study of anemia after late introduction of everolimus in the immunosuppressive treatment of renal transplant patients. Transpl Proc 39 (2007) 2242
3. Quesniaux V.F.J., Wehrli S., Steiner C., et al. The immunosuppressant rapamycin blocks in vitro responses to hematopoietic cytokines and inhibits recovering but not steady-state hematopoiesis in vivo. Blood 84 (1994) 1543
4. Hong J.C., and Kahan B.D. Sirolimus-induced thrombocytopenia and leukopenia in renal transplant recipients: risk factors, incidence, progression, and management. Transplantation 69 (2000) 2085
5. Thaunat O., Beaumont C., Chatenoud L., et al. Anemia after late introduction of sirolimus may correlate with biochemical evidence of a chronic inflammatory state. Transplantation 80 (2005) 1212
6. Maiorano A., Stallone G., and Schena A. Sirolimus interferes with iron homeostasis in renal transplant recipients. Transplantation 82 (2006) 908
7. Levy G., Schmidli H., Punch J., et al. Safety, tolerability, and efficacy of everolimus in de novo liver transplant recipients: 12- and 36-month results. Liver Transpl 12 (2006) 1640
8. Tenderich G., Fuchs U., Zittermann A., et al. Comparison of sirolimus and everolimus in their effects on blood lipid profiles and haematological parameters in heart transplant recipients. Clin Transplant 21 (2007) 536